menu
    • menu

    Company profile for Lipocine

    NEW Drugs in Dev: 6
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes TLANDO, LPCN 1144, TLANDO XR ("LPCN 1111"), LPCN 1148 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men....
    Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes TLANDO, LPCN 1144, TLANDO XR ("LPCN 1111"), LPCN 1148 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men. Lipocine received a complete response letter from the FDA related to TLANDO on November 8, 2019.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    LipocineUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    675 Arapeen Drive, Suite 202 Salt Lake City
    Telephone
    Telephone
    801.994.7383
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.lipocine.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    International Sweetener Colloquium

    Not Confirmed

    envelop Contact Supplier

    International Sweetener Colloquium

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lipocine Completes LPCN 1154 Phase 3 Trial Enrollment
    Lipocine Completes LPCN 1154 Phase 3 Trial Enrollment

    20 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lipocine-announces-completion-of-enrollment-and-dosing-in-phase-3-trial-of-lpcn-1154-in-postpartum-depression-ppd-302664877.html

    PR NEWSWIRE
    20 Jan 2026
    Share Share
    Lipocine Advances LPCN 1154 In Postpartum Depression Ph3 Trial
    Lipocine Advances LPCN 1154 In Postpartum Depression Ph3 Trial

    12 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lipocine-reports-encouraging-progress-post-second-interim-safety-review-in-phase-3-trial-of-lpcn-1154-in-postpartum-depression-ppd-302657662.html

    PR NEWSWIRE
    12 Jan 2026
    Share Share
    Lipocine's LPCN 1154 Phase 3 Study Reaches 80% Enrollment
    Lipocine's LPCN 1154 Phase 3 Study Reaches 80% Enrollment

    16 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lipocines-ppd-phase-3-study-lpcn-1154-hits-80-enrollment-milestone-302642892.html

    PR NEWSWIRE
    16 Dec 2025
    Share Share
    Lipocine Showcases LPCN 1154 Phase 3 Trial Safety In Postpartum
    Lipocine Showcases LPCN 1154 Phase 3 Trial Safety In Postpartum

    18 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lipocine-highlights-promising-interim-safety-profile-in-phase-3-trial-of-lpcn-1154-in-postpartum-depression-ppd-302617859.html

    PR NEWSWIRE
    18 Nov 2025
    Share Share
    Lipocine Reports Q3 2025 Financial Results
    Lipocine Reports Q3 2025 Financial Results

    06 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lipocine-announces-financial-results-for-the-third-quarter-ended-september-30-2025-302606486.html

    PR NEWSWIRE
    06 Nov 2025
    Share Share
    Lipocine reveals Q2 financial results ending June 30, 2025
    Lipocine reveals Q2 financial results ending June 30, 2025

    06 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lipocine-announces-financial-results-for-the-second-quarter-ended-june-30-2025-302521416.html

    PR NEWSWIRE
    06 Aug 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search